FDA Approves Lembaz First Survival Drug For Niemann-Pick
The FDA approved Lembaz on November 17 for patients whose Niemann-Pick disease type C symptoms began before age 6, after treated patients showed median survival of 8.5 years against 4.9 years for matched external controls.
Edited and fact-checked by Stephen Sprague
Lembaz reaches treatment sites in early December, and the hearing evaluations written into its label become part of every family's treatment calendar.
The Food and Drug Administration approved Lembaz (adrabetadex) injection on Tuesday, November 17. It is the first treatment shown to help people with infantile-onset Niemann-Pick disease type C live longer, and the approval covers adults and children who weigh at least 7 kg, about 15 pounds, and whose neurological symptoms began before age 6.
Niemann-Pick disease type C is a rare inherited lysosomal storage disorder that affects an estimated 1 in 150,000 people, and it leaves the body unable to process cholesterol and other fats inside cells. Those substances accumulate in the brain over time, and children lose movement, coordination and the ability to swallow as the disease progresses.
Regulators built the survival finding on 36 patients treated with Lembaz across three clinical studies and an expanded access program, set against a matched external control group. Treated patients carried a 55 percent lower risk of death, with median survival of 8.5 years against 4.9 years for the controls, and the benefit held whether or not a patient was also taking miglustat.
A trained health care provider delivers Lembaz by injection into the spinal canal every two weeks, a schedule that puts a procedure visit at the center of family life for as long as treatment continues. The label carries a boxed warning for hearing impairment, including permanent hearing loss, and it requires a comprehensive hearing evaluation before the first dose and regular evaluations after that, with dose adjustments tied to the results.
Acting FDA Commissioner Kyle Diamantas called the approval an important milestone and said a treatment shown to help adults and children with the disease live longer now exists for the first time. Two earlier therapies were approved for this disease, and neither has been shown to reduce the risk of death, while Lembaz received Breakthrough Therapy designation and its approval went to Mandos, LLC, a subsidiary of Beren Therapeutics.
Families weighing the drug should hold one limit in view, because the survival comparison rests on matched external controls and the matching carries part of the result. Common side effects in the FDA summary include problems with hearing, balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea and cough. Beren expects Lembaz to reach treatment sites nationwide in early December.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.